Back to drug safety directory
Centrally-acting muscle relaxantReviewed May 16, 2026

Methocarbamol (Robaxin) and Ketamine Therapy | Tovani Health

Robaxin (Methocarbamol)Centrally-acting muscle relaxant

Verdict at Tovani Health

Compatible; mild sedation, lighter interaction profile than cyclobenzaprine.

Methocarbamol and ketamine are compatible. It is one of the lighter-profile muscle relaxants for KAP planning: less sedating than cyclobenzaprine, fewer cardiovascular concerns than tizanidine.

If you take Robaxin regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.

How Robaxin interacts with ketamine

Methocarbamol's exact mechanism is unclear but appears to act centrally to reduce muscle spasm. Mild sedation is the main side effect.

What we do at intake

Disclose dose and frequency. Continue as needed.

Bottom line

Methocarbamol and ketamine are compatible. It is one of the lighter-profile muscle relaxants for KAP planning: less sedating than cyclobenzaprine, fewer cardiovascular concerns than tizanidine.

Frequently Asked Questions

Is Robaxin a better KAP choice than Flexeril?

From an interaction standpoint, generally yes. It is less sedating and avoids the TCA-like serotonergic profile.

Ready to find out if at-home ketamine fits your situation?

We’ll note that you’re on Robaxin (Methocarbamol) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.

FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.

Sources

The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.

  1. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535

    Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).

Clinically reviewed

Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.

This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.